Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

NCT00097370 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
78
Enrollment
INDUSTRY
Sponsor class

Stopped Study terminated by sponsor (29 Sep 2010). Subjects eligible to continue mepolizumab treatment were transferred into the compassionate use program (MHE104317)

Conditions

Interventions

Sponsor

GlaxoSmithKline